Search

Displaying results 11 - 20 of 46 in total
  1. Indication

    Primary Immunodeficiency

    go.drugbank.com/conditions/DBCOND0034592
    Drugs: Hyaluronidase (human recombinant)
  2. Indication

    Gastroesophageal Junction Cancer

    go.drugbank.com/conditions/DBCOND0043630
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  3. Indication

    Intermediate risk Advanced Renal Cell Cancer

    go.drugbank.com/conditions/DBCOND0127584
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  4. Indication

    Metastatic Cancer of the Gastroesophageal Junction (GEJ)

    go.drugbank.com/conditions/DBCOND0173127
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  5. Indication

    Unresectable, advanced metastatic Esophageal squamus cell carcinoma (ESCC)

    go.drugbank.com/conditions/DBCOND0173462
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  6. Indication

    Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)

    go.drugbank.com/conditions/DBCOND0145164
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  7. Indication

    Unresectable Alveolar Soft Part Sarcoma

    go.drugbank.com/conditions/DBCOND0131862
    Drugs: Atezolizumab · Hyaluronidase (human recombinant)
  8. Indication

    Advanced Gastroesophageal Junction Adenocarcinoma

    go.drugbank.com/conditions/DBCOND0120535
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  9. Indication

    Poor Risk Advanced Renal Cell Cancer

    go.drugbank.com/conditions/DBCOND0145158
    Drugs: Hyaluronidase (human recombinant) · Nivolumab
  10. Indication

    Unresectable Urothelial Carcinoma

    go.drugbank.com/conditions/DBCOND0116739
    Drugs: Hyaluronidase (human recombinant) · Nivolumab